# Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

> **NCT06276868** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 71 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Dalcilib+letrozole+HP treatment group

## Key facts

- **NCT ID:** NCT06276868
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-20
- **Primary completion:** 2025-07-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06276868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06276868, "Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06276868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*